Cellmic, LLC — Department of Health and Human Services SBIR Phase II: NIAID

Description

Proposes an advanced Ebola and Marburg disease telemonitoring and assessment platform that will enable the digital modernization of point of care diagnosticsdisease surveillanceand healthcare screening by minimally trained personnel at the point of careOffering a complete diagnostics solutionthe platform includes a microfluidics assay for the detection of infections caused by Ebola and Marburg filovirusesa universal microfluidics reader and a unique telemonitoring service to communicate test results with HIPAA compliant remote database that can be accessed through a web interfaceThe testing process will takeminutes per patientand will require less than a drop of blood to performThe system will be validated with disease sera obtained from non human primateshuman sera from Ebola virus disease survivorsand field tested at a clinic in the Democratic Republic of CongoAlthough the primary focus of the project is the digital detection and monitoring of filovirus infectionsthe technology can be expanded for the detection of other infectionssuch as those caused by newly emerging virusesThis final integrated system will provide a rapidreliablereal time and digital solution for remote monitoring of Ebola and Marburg virus diseasesThe phase II efforts to further advance development of this platform will optimize the system sensitivity and accuracycreate user friendly interfaces and procedures for field operationsand refine the system specifications to address technical and market requirements to reach a successful product launch